Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 33 Show results per page	View Search Criteria \| Help With Results


1.		Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Active				16 to 75				Other				CGC05MK1002 NCT00188149

Last Modified: 10/7/2008 First Published: 12/1/1998


2.		Phase II/III Randomized Study of Bleomycin, Cisplatin, and Etoposide (BEP) Versus Bleomycin, Cisplatin, Etoposide, and Paclitaxel (T-BEP) in Men With Intermediate Prognosis Germ Cell Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				16 to 50				Other				EORTC-30983 NCT00003643

Last Modified: 1/11/2009 First Published: 10/1/2001


3.		Phase III Randomized Study of Response-Based Chemotherapy With Doxorubicin, Bleomycin, Vincristine, Etoposide, Prednisone, and Cyclophosphamide With or Without Dexamethasone, Etoposide, Cytarabine, Cisplatin, and/or Radiotherapy in Children With Newly Diagnosed Intermediate-Risk Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				21 and under				NCI				COG-AHOD0031 NCT00025259, AHOD0031

Last Modified: 5/18/2007 First Published: 7/1/2002


4.		Phase III Randomized Study of Bleomycin, Doxorubicin, Etoposide, Mechlorethamine, Vinblastine, Vincristine, and Prednisone (Stanford V) Versus Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) in Patients With Previously Untreated Advanced Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 60				Other				BNLI-STANFORDV EU-20206, NCT00041210

Last Modified: 1/6/2009 First Published: 11/1/2002


5.		Phase III Randomized Study of Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone (BEACOPP) Versus Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) in Patients With Stage III or IV Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				16 to 60				Other				EORTC-20012 GELA-EORTC-20012, BNLI-EORTC-20012, GELCAB-EORTC-20012, NORDICLG-EORTC-20012, CAN-NCIC-EORTC-20012, ALLG-HD04, hd8, NCT00049595

Last Modified: 10/23/2008 First Published: 12/21/2002


6.		Phase III Study of Surgery Followed By Compressed Cisplatin, Etoposide, and Bleomycin in Children With Newly Diagnosed Low- or Intermediate-Risk Extracranial Germ Cell Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 21 at diagnosis				NCI				COG-AGCT0132 NCT00053352, AGCT0132

Last Modified: 8/9/2007 First Published: 2/18/2005


7.		Phase III Randomized Study of Bleomycin, Etoposide, and Cisplatin With or Without Dose-Dense Sequential Combination Chemotherapy in Patients With Poor Prognosis Stage II or III Non-Seminomatous Germ Cell Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Over 16				Other				FRE-FNCLCC-GETUG-13/0206 EU-20502, NCT00104676


8.		ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-Cell Lymphoma and Age-Adjusted IPI of 1

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 59				Other				LNH03-2B NCT00140595

Last Modified: 8/9/2007 First Published: 12/22/2005


9.		Phase III Study of Observation and/or Chemotherapy Comprising Etoposide, Carboplatin, and Bleomycin With or Without Vinblastine, Ifosfamide, and Cisplatin After Surgical Resection or Biopsy in Pediatric Patients With Extracranial Malignant Germ Cell Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				Under 18				Other				CCLG-GC-2005-04 EUDRACT-2004-002503-33, EU-20584, NCT00274950

Last Modified: 1/24/2007 First Published: 5/5/2006


10.		Phase III Randomized Study of Short- Versus Long-Infusion Schedule of Bleomycin in Patients Who are Undergoing Combination Chemotherapy Comprising Bleomycin, Etoposide, and Cisplatin for Good-Prognosis, Metastatic Germ Cell Cancer of the Testes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Active				18 to 50				Other				BARTS-TE3 EU-20608, ISRCTN08648791, NCT00324298

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute